The meaning of residual disease in breast cancer
Tackling residual disease in breast cancer
Role of ctDNA in MRD
Capecitabine remains the adjuvant standard of care for TNBC with residual disease | Ingrid Mayer
Management of residual disease in triple negative breast cancer
Prognostic impact of micrometastatic residual disease in node-negative breast cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
‘We’re Very Hopeful’: Research Advances for Breast Cancer and Minimal Residual Disease
For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
Residual tumor treatment in mutant BRCA-1 triple-negative breast cancer
The predictive value of treatment response after neoadjuvant therapy
Potential role of ctDNA for early-stage breast cancer
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer
Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer
Evaluation of Breast Specimens after Neoadjuvant Chemotherapy
Case Review: T-DM1 for Residual HER2+ Breast Cancer
MBCC 2017: Residual cancer burden may be better outcome measure than pCR
ctDNA assay for detection of recurrent disease in patients with early-stage breast cancer
